An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
Information source: Amgen
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenic Purpura
Intervention: Romiplostim (Biological)
Phase: Phase 3
Status: Completed
Sponsored by: Amgen Official(s) and/or principal investigator(s): MD, Study Director, Affiliation: Amgen
Summary
This protocol will provide open label romiplostim to adult thrombocytopenic subjects.
Romiplostim will be administered by subcutaneous injection once per week. Dose adjustment
will be based on platelet counts, and will be allowed throughout the duration of the study.
Rescue therapies are allowed at any time during the study. Reductions in concurrent ITP
therapies may occur at any time when platelet counts are > 50,000.
Clinical Details
Official title: An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Adverse Events
Secondary outcome: Platelet Response (Definition 1)Platelet Response (Definition 2)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject has a diagnosis of immune (idiopathic) thrombocytopenic purpura per the
American Society of Hematology guidelines
- If Subject is > 60 years of age, subject has a written bone marrow aspiration and/or
biopsy report consistent with a diagnosis of ITP
- Subject has received at least 1 prior therapy for ITP
- Subject's platelet count is ≤ 30,000 or the subject is experiencing bleeding that is
uncontrolled with conventional therapies
- Subject (or legally-acceptable representative) is willing and able to provide written
informed consent
Exclusion Criteria:
- Subject has a history of hematological malignancy, myeloproliferative disorder,
myelodysplastic syndrome (MDS), or bone marrow stem cell disorder
- Subject has participated in any study evaluating PEG-rHuMGDF, recombinant human
thrombopoietin (rHuTPO), or related platelet product
- Subject has a known hypersensitivity to any recombinant E coli-derived product
- Subject has received any therapeutic drug or device that is not approved by the local
regulatory health agency for any indication within 4 weeks of Screening
- Subject is of reproductive potential and is not using adequate contraceptive
precautions, in the judgment of the investigator
- Subject is pregnant or breast feeding
- Investigator has concerns regarding the subject's ability to comply with the protocol
procedures
Locations and Contacts
Additional Information
AmgenTrials clinical trials website
Starting date: February 2005
Last updated: January 11, 2012
|